Volta Labs, a bioautomation company developing solutions to streamline the upstream workflows in genomic sequencing, recently announced it raised $20 million in a Series A funding. The company has raised over $25M in funding to date.
The company, which was founded in 2018 by Udayan Umapathi, started as a simple exploration with water droplets on a printed circuit board during Umapathi’s graduate work at the MIT Media Lab. This work evolved into building biological automation from the ground up, with a mission to fast-track the next genome discovery. In 2019, the company raised its seed funding from Maverick Ventures and other top VCs, with Will Langford onboarding later that year as a co-founder and Head of Engineering.
Volta Labs’ platform-based solution for sequencing sample preparation is built on a dramatically simplified version of digital fluidics that leverages several novel inventions in fluidic manipulation. The platform integrates components from electronics, automation, and materials industries with a modern software stack. This has led to novel and enabling sample prep advancements that will be unveiled at the genomics conference AGBT in June of this year.
The company has developed several technology demonstration prototypes and deployed them at leading research institutions across the country. While Volta’s current focus is on sequencing sample prep, the company envisions going after a variety of applications in the long run. The company has already developed the proof of concepts for workflows in synthetic biology and workflows for the quantification of proteins.
In addition to John Stuelpnagel, who is joining as a strategic investor and advisor, the round is supported by multiple other titans of the genomics industry. David Singer (Maverick Ventures) was the founding CEO of Affymetrix and a board member of Pacific Biosciences (PACB) and Seer (SEER). Additional supporters include Anne Wojcicki, the CEO of 23andMe, and existing investor Paul McEwan, co-founder Kapa Biosystems, Agencourt Biosystems.
The capital from this latest investment will accelerate the development of a sequencer-agnostic front-end platform for commercial release in 2023, with a limited release program by the end of this year. To support this effort, the company is actively hiring across engineering, applications, research and development, and sales.
Udayan Umapathi, Co-founder and CEO of Volta Labs
This is a golden era for tool building in biology. It’s like the early days of computing wherein the foundational technologies are still being built out. From an application standpoint, we are starting with sequencing sample prep, but this is only the tip of the iceberg. Together — the engineers, biologists, and systems thinkers on our team — we are building a universal machine any biologist will want.
